{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:20:56Z","timestamp":1787988056240,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.eclinm.2022.101569","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T05:57:30Z","timestamp":1658469450000},"page":"101569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"special_numbering":"C","title":["Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1\/2 trial"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0148-7194","authenticated-orcid":false,"given":"Joon Young","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Suk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Yeon","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Sik","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hwa","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joong Sik","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Tae","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang Wook","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2120-6265","authenticated-orcid":false,"given":"Young Keun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yun","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Joo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angeles","family":"Ceregido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Solmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Philippot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra C.","family":"Walls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6019-8675","authenticated-orcid":false,"given":"David","family":"Veesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil P.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hwa","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3370-0735","authenticated-orcid":false,"given":"Su Jeen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Wook","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Keun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Jin","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2022.101569_bib0001","unstructured":"World Health Organization. Coronavirus disease 2019 (COVID-19): situation report. Available at: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/situation-reports. Accessed 31 January 2022."},{"issue":"1","key":"10.1016\/j.eclinm.2022.101569_bib0002","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41541-021-00393-6","article-title":"Scientific rationale for developing potent RBD-based vaccines targeting COVID-19","volume":"6","author":"Kleanthous","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"5","key":"10.1016\/j.eclinm.2022.101569_bib0003","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","article-title":"Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.eclinm.2022.101569_bib0004","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.eclinm.2022.101569_bib0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.eclinm.2022.101569_bib0006","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1016\/j.cell.2021.09.015","article-title":"Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines","volume":"184","author":"Walls","year":"2021","journal-title":"Cell"},{"issue":"7862","key":"10.1016\/j.eclinm.2022.101569_bib0007","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41586-021-03530-2","article-title":"Adjuvanting a subunit COVID-19 vaccine to induce protective immunity","volume":"594","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.eclinm.2022.101569_bib0008","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","article-title":"Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity","volume":"29","author":"Morel","year":"2011","journal-title":"Vaccine"},{"issue":"14","key":"10.1016\/j.eclinm.2022.101569_bib0009","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.vaccine.2013.01.042","article-title":"Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines","volume":"31","author":"Tavares Da Silva","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.eclinm.2022.101569_bib0010","series-title":"Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials: Guidance for Industry","year":"2007"},{"key":"10.1016\/j.eclinm.2022.101569_bib0011","unstructured":"National Institute for Biological Standards and Control (NIBSC). First WHO International Reference Panel for anti-SARS-CoV-2 immunoglobulin (NIBSC code: 20\/268). 2020; 1-2. Available at: https:\/\/www.nibsc.org\/documents\/ifu\/20-268.pdf. Accessed 2 January 2022."},{"issue":"5","key":"10.1016\/j.eclinm.2022.101569_bib0012","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/infdis\/jiab124","article-title":"Longitudinal assessment of antisevere acute respiratory syndrome coronavirus 2 immune responses for six months based on the clinical severity of coronavirus disease 2019","volume":"224","author":"Noh","year":"2021","journal-title":"J Infect Dis"},{"issue":"10249","key":"10.1016\/j.eclinm.2022.101569_bib0013","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.eclinm.2022.101569_bib0014","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.eclinm.2022.101569_bib0015","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.eclinm.2022.101569_bib0016","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"40","key":"10.1016\/j.eclinm.2022.101569_bib0017","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1016\/j.vaccine.2021.08.081","article-title":"SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1","volume":"39","author":"Law","year":"2021","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.eclinm.2022.101569_bib0018","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.vaccine.2019.04.048","article-title":"Safety of AS03-adjuvanted influenza vaccines: a review of the evidence","volume":"37","author":"Cohet","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.eclinm.2022.101569_bib0019","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development and evaluation of AS03, an adjuvant system containing alpha-tocopherol and squalene in an oil-in-water emulsion","volume":"11","author":"Garcon","year":"2012","journal-title":"Expert Rev Vaccines"},{"issue":"25","key":"10.1016\/j.eclinm.2022.101569_bib0020","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMc2114706","article-title":"Neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine serum","volume":"385","author":"Uriu","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.eclinm.2022.101569_bib0021","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.eclinm.2022.101569_bib0022","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1016\/j.vaccine.2019.06.039","article-title":"An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines","volume":"37","author":"Hauser","year":"2019","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.eclinm.2022.101569_bib0023","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1473-3099(21)00764-7","article-title":"Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study","volume":"22","author":"Sridhar","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.eclinm.2022.101569_bib0024","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","article-title":"Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19","volume":"27","author":"Ward","year":"2021","journal-title":"Nat Med"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022002991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537022002991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:29:26Z","timestamp":1781526566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537022002991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":24,"alternative-id":["S2589537022002991"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101569","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.30.22273143","asserted-by":"object"}]},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1\/2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2022.101569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101569"}}